Fast, reliable solutions for oncology workflows: Illumina and Pillar team up at ESMO 2025 to showcase a powerful combination of NGS tests
At ESMO 2025, Illumina teams up with Pillar Biosciences to showcase their powerful combination of NGS tests
At ESMO 2025, Illumina teams up with Pillar Biosciences to showcase their powerful combination of NGS tests
September 4, 2025 – Pillar Biosciences, Inc., a leading provider of kitted next-generation sequencing (NGS) panels, and regulatory automation provider Platomics are collaborating to streamline compliance for next-generation sequencing (NGS) tests under the EU’s In Vitro Diagnostic Regulation (IVDR). Now that IVDR has come into force, clinical laboratories must provide extensive regulatory documentation. Labs are
May 27, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received $34.5M in funding, including a strategic investment from Illumina, and structured financing from Soleus Capital and investments from existing investors. Proceeds from this financing will be leveraged to advance Pillar’s commercial activities including headcount and infrastructure to support
Pillar Biosciences Raises $34.5M in Funding Read More »
April 3, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received nationwide Medicare coverage by the Centers for Medicare & Medicaid Services (CMS) for oncoReveal® CDx pan-cancer solid tumor in vitro diagnostic (IVD) NGS kit. oncoReveal® CDx is a NGS based IVD kit that uses Pillar’s proprietary SLIMamp (Stem-Loop
Collaboration aims to accelerate automation of rapid NGS testing February 18, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has entered into a strategic NGS automation application development agreement and co-marketing partnership with Hamilton Company. As part of this agreement, Hamilton will develop automation scripts and supporting technical and commercial literature for selected,
In 2024, Pillar Biosciences made significant strides in advancing our mission of Decision Medicine™ and improving cancer diagnostics through rapid, innovative Next-Generation Sequencing (NGS) kitted solutions. We’ve made substantial advancements and improved access to precision oncology solutions globally. Here is a summary of select key achievements in 2024: FDA Approval of oncoReveal® CDx In April, Pillar
Reflecting on 2024: A Year of Growth, Innovation, and Partnership at Pillar Biosciences Read More »
Agreement aims to enhance Pillar’s PiVat® bioinformatics platform with downstream reporting capabilities. NATICK, Mass – January 7, 2025 – Pillar Biosciences, Inc. has entered into a strategic five-year licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) for its proprietary OncoKB™ precision medicine knowledgebase. OncoKB™ is the first somatic human variant database to receive FDA
Originally posted on Genomeweb Premium by Andrew P. Han September 12, 2024 NEW YORK – Memorial Sloan Kettering Cancer Center (MSK) is in the process of implementing a new rapid sequencing-based cancer panel to complement ongoing comprehensive genomic profiling (CGP). The assay, branded as MSK-React, is based on a new panel from Pillar Biosciences, recently launched as
Natick, MA – November 14, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2024 Association for Molecular Pathology (AMP) Annual Meeting in Vancouver, BC, Canada. The company and scientific collaborators will collectively present ten studies and host three corporate workshops, showcasing their latest advancements in Next-Generation Sequencing (NGS) technology and oncology
Natick, MA – October 24, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced that they have been granted a unique CPT® Proprietary Laboratory Analyses (PLA) code 0523U from the American Medical Association (AMA) for their FDA approved oncoReveal™ CDx pan-cancer solid tumor in vitro diagnostic (IVD) NGS kit. oncoReveal™ CDx is a NGS